|

Potential Role of Sirtuins As Epigenetic Biomarkers of the Patient with Atherosclerosis or Calcific Aortic Stenosis

RECRUITINGSponsored by IRCCS SYNLAB SDN
Actively Recruiting
SponsorIRCCS SYNLAB SDN
Started2023-10-19
Est. completion2025-10
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06337227

Summary

The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with atherosclerosis or calcific aortic stenosis with and without diabetes older than 18 years of either sex;
* Patients without atherosclerosis undergoing surgical procedure for endocarditis;
* Patients who will have signed informed consent

Exclusion Criteria:

* Patients for whom biological material cannot be recovered for study purposes;
* Patients who refuse to participate in the study

Conditions2

Atherosclerosis and Calcific Aortic Stenosis with and Without DiabetesDiabetes

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.